NCT01224418已完成4 期
Clinical Study to Evaluate the Efficacy of Tacrolimus in Active Rheumatoid Arthritis Patients Shown Unsuccessful Response Against Methotrexate: Non-comparative, Single Arm, Multi-center, Phase 4 Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 50
- 主要终点
- ACR20 response rate compared to baseline
研究概览
简要总结
This study is to evaluate efficacy of 6 months treatment of tacrolimus in active Rheumatoid Arthritis patients who showed unsuccessful response against methotrexate.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with more than 6 months history of rheumatoid arthritis according to ACR criteria
- •Patients who have been treated unsuccessfully to more than single DMARDs including methotrexate at the discretion of investigator
- •ESR ≥ 30 mm/h or CRP ≥ 1.0 mg/dL (ESR: Erythrocyte Sedimentation Rate, CRP: C-Reactive Protein)
- •Patients are required to have at least 3 of 66 joints assessed as swollen
- •Patients are required to have at least 6 of 68 joints assessed as painful with pressure
排除标准
- •Pregnant or breast-feeding patients. Patients who plan to bear children or breast-feed during the study and within 6 month after completion of study
- •Previous experience of tacrolimus (ointment excluded)
- •Renal impairment or serum creatinine > 1.4 mg/dL
- •Liver function failure as follows: viral hepatitis, non-viral hepatitis, cirrhosis, SGOT/SGPT > 2x upper limit normal
- •Patients with history of pancreatitis, glucose intolerance or complication or who indicates any of the following criteria:Blood glucose level >110mg/dl before the meal and >200mg/dl after the meal HbA1c > 6.4%
- •Cardiac disease(ischemic heart disease, treatment-requiring arrhythmia, heart failure)or complications
- •Other investigational drug within last 30 days
- •Patients who have been treated with infliximab, adalimumab, or leflunomide within 8 weeks of start of the study
研究组 & 干预措施
Tacrolimus group
Experimental
干预措施: Tacrolimus (Drug)
结局指标
主要结局
ACR20 response rate compared to baseline
时间窗: Baseline and up to 6 months
(ACR20: 20% improvement in American College of Rheumatology Core Set)
次要结局
- ACR50 response rate compared to baseline(Baseline and up to 6 months)
- ACR70 response rate compared to baseline(Baseline and up to 6 months)
- Changes from baseline in 100mm pain VAS (Visual Analogue Scale)(Baseline and up to 6 months)
- Safety assessed by the incidence of adverse event and abnormalities in clinical laboratory test(For 6 months)
研究者
相似试验
已完成
4 期
Study to Evaluate the Efficacy of Tacrolimus in Rheumatoid Arthritis Patients Shown Unsuccessful Response to MethotrexateRheumatoid ArthritisNCT01224041Astellas Pharma Inc78
已完成
4 期
A Study is to Assess Efficacy and Safety of Tacrolimus in Active Rheumatoid Arthritis Patients Who Showed Unsuccessful Response to Existing Disease Modifying Antirheumatic Drugs (DMARDs)Rheumatoid ArthritisNCT01511003Astellas Pharma Inc128
已完成
4 期
Efficacy and Safety Study of Tacrobell to Treat Rheumatoid ArthritisRheumatoid ArthritisNCT01746680Chong Kun Dang Pharmaceutical111
已完成
不适用
Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with infliximab and methotrexateRheumatoid ArthritisJPRN-UMIN000000512Rheumatosurgery, Osaka City University Medical School30
Unknown
4 期
Efficacy and Safety of a Reduced Immunosuppression vs. Standard Triple Therapy in Senior Renal Transplant RecipientsImmunosuppression After Renal TransplantationNCT02453867Klemens Budde400